C Norman Coleman

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8675185/publications.pdf

Version: 2024-02-01

144 papers	6,989 citations	87723 38 h-index	66788 78 g-index
151 all docs	151 docs citations	151 times ranked	7375 citing authors

#	Article	IF	Citations
1	DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nature Communications, 2017, 8, 15618.	5.8	1,194
2	Medical Management of the Acute Radiation Syndrome: Recommendations of the Strategic National Stockpile Radiation Working Group. Annals of Internal Medicine, 2004, 140, 1037.	2.0	618
3	Pretreatment Nomogram for Prostate-Specific Antigen Recurrence After Radical Prostatectomy or External-Beam Radiation Therapy for Clinically Localized Prostate Cancer. Journal of Clinical Oncology, 1999, 17, 168-168.	0.8	361
4	Radiotherapy: Changing the Game in Immunotherapy. Trends in Cancer, 2016, 2, 286-294.	3.8	270
5	Models for Evaluating Agents Intended for the Prophylaxis, Mitigation and Treatment of Radiation Injuries Report of an NCI Workshop, December 3â€“4, 2003. Radiation Research, 2004, 162, 711-728.	0.7	230
6	Radiation Injury After a Nuclear Detonation: Medical Consequences and the Need for Scarce Resources Allocation. Disaster Medicine and Public Health Preparedness, 2011, 5, S32-S44.	0.7	183
7	Gene Expression Profiling of Breast, Prostate, and Glioma Cells following Single versus Fractionated Doses of Radiation. Cancer Research, 2007, 67, 3845-3852.	0.4	167
8	Therapy-Induced Senescence: Opportunities to Improve Anticancer Therapy. Journal of the National Cancer Institute, 2021, 113, 1285-1298.	3.0	156
9	Assessment of Biodosimetry Methods for a Mass-Casualty Radiological Incident. Health Physics, 2013, 105, 540-554.	0.3	150
10	Molecular and Cellular Biology of Moderate-Dose (1â€“10 Gy) Radiation and Potential Mechanisms of Radiation Protection: Report of a Workshop at Bethesda, Maryland, December 17â€“18, 20011. Radiation Research, 2003, 159, 812-834.	0.7	144
11	MEDICINE: Modulation of Radiation Injury. Science, 2004, 304, 693-694.	6.0	127
12	Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose?. , 2021, 9, e002038.		124
13	Patterns of presentation of Hodgkin disease. Implications for etiology and pathogenesis. Cancer, 1993, 71, 2062-2071.	2.0	123
14	Long term results of stereotactic brachytherapy used in the initial treatment of patients with glioblastomas. Cancer, 1994, 73, 3029-3036.	2.0	116
15	The â€œRTRâ€•Medical Response System for Nuclear and Radiological Mass-Casualty Incidents: A Functional TRiage-TReatment-TRansport Medical Response Model. Prehospital and Disaster Medicine, 2009, 24, 167-178.	0.7	97
16	Medical Response to a Radiologic/Nuclear Event: Integrated Plan From the Office of the Assistant Secretary for Preparedness and Response, Department of Health and Human Services. Annals of Emergency Medicine, 2009, 53, 213-222.	0.3	84
17	Literature Review and Global Consensus on Management of Acute Radiation Syndrome Affecting Nonhematopoietic Organ Systems. Disaster Medicine and Public Health Preparedness, 2011, 5, 183-201.	0.7	78
18	Understanding High-Dose, Ultra-High Dose Rate, and Spatially Fractionated Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2020, 107, 766-778.	0.4	70

#	Article	IF	Citations
19	Improving the Predictive Value of Preclinical Studies in Support of Radiotherapy Clinical Trials. Clinical Cancer Research, 2016, 22, 3138-3147.	3.2	68
20	Radiologic and nuclear events: contingency planning for hematologists/oncologists. Blood, 2008, 111, 5440-5445.	0.6	65
21	Allocation of Scarce Resources After a Nuclear Detonation: Setting the Context. Disaster Medicine and Public Health Preparedness, 2011, 5, S20-S31.	0.7	63
22	Biological Dosimetry by the Triage Dicentric Chromosome Assay: Potential Implications for Treatment of Acute Radiation Syndrome in Radiological Mass Casualties. Radiation Research, 2011, 175, 397-404.	0.7	62
23	Triage and Treatment Tools for Use in a Scarce Resources-Crisis Standards of Care Setting After a Nuclear Detonation. Disaster Medicine and Public Health Preparedness, 2011, 5, S111-S121.	0.7	61
24	NCIâ€“RTOG Translational Program Strategic Guidelines for the Early-Stage Development of Radiosensitizers. Journal of the National Cancer Institute, 2013, 105, 11-24.	3.0	60
25	Exploiting sensitization windows of opportunity in hyper and hypo-fractionated radiation therapy. Journal of Thoracic Disease, 2014, 6, 287-302.	0.6	60
26	Prognostic factors for patients with hodgkin disease in first relapse. Cancer, 1993, 71, 2613-2620.	2.0	55
27	Harnessing the Potential of Radiation-Induced Immune Modulation for Cancer Therapy. Cancer Immunology Research, 2013, 1, 280-284.	1.6	55
28	Radioprotectors and Radiomitigators for Improving Radiation Therapy: The Small Business Innovation Research (SBIR) Gateway for Accelerating Clinical Translation. Radiation Research, 2015, 184, 235-248.	0.7	54
29	Fractionated Radiation Therapy Can Induce a Molecular Profile for Therapeutic Targeting. Radiation Research, 2010, 174, 446-458.	0.7	50
30	Biodosimetry: Medicine, Science, and Systems to Support the Medical Decision-Maker Following a Large Scale Nuclear or Radiation Incident. Radiation Protection Dosimetry, 2016, 172, 38-46.	0.4	50
31	Precision Oncology and Genomically Guided Radiation Therapy: A Report From the American Society for Radiation Oncology/American Association of Physicists in Medicine/National Cancer Institute Precision Medicine Conference. International Journal of Radiation Oncology Biology Physics, 2018, 101, 274-284.	0.4	50
32	Preclinical Data on Efficacy of 10 Drug-Radiation Combinations: Evaluations, Concerns, and Recommendations. Translational Oncology, 2016, 9, 46-56.	1.7	48
33	Stem Cells, Multiorgan Failure in Radiation Emergency Medical Preparedness: A U.S./European Consultation Workshop. Stem Cells, 2009, 27, 1205-1211.	1.4	47
34	Tumor Hypoxia: Chicken, Egg, or a Piece of the Farm?. Journal of Clinical Oncology, 2002, 20, 610-615.	0.8	46
35	Radiation-Induced Long Noncoding RNAs in a Mouse Model after Whole-Body Irradiation. Radiation Research, 2018, 189, 251.	0.7	44
36	In vivo somatic mutation in the lymphocytes of Hodgkin's disease patients. Environmental and Molecular Mutagenesis, 1991, 18, 6-13.	0.9	42

#	Article	IF	Citations
37	Defining Molecular Signature of Pro-Immunogenic Radiotherapy Targets in Human Prostate Cancer Cells. Radiation Research, 2014, 182, 139-148.	0.7	41
38	NS-398, ibuprofen, and cyclooxygenase-2 RNA interference produce significantly different gene expression profiles in prostate cancer cells. Molecular Cancer Therapeutics, 2009, 8, 261-273.	1.9	39
39	Resource Allocation After a Nuclear Detonation Incident: Unaltered Standards of Ethical Decision Making. Disaster Medicine and Public Health Preparedness, 2011, 5, S46-S53.	0.7	39
40	Differential Expression of Stress and Immune Response Pathway Transcripts and miRNAs in Normal Human Endothelial Cells Subjected to Fractionated or Single-Dose Radiation. Molecular Cancer Research, 2014, 12, 1002-1015.	1.5	38
41	Wide-field radiation therapy with or without chemotherapy for patients with Hodgkin disease in relapse after initial combination chemotherapy. Cancer, 1993, 72, 207-212.	2.0	37
42	Long and short non-coding RNA and radiation response: a review. Translational Research, 2021, 233, 162-179.	2.2	36
43	Addressing Cancer Disparities Among American Indians through Innovative Technologies and Patient Navigation: The Walking Forward Experience. Frontiers in Oncology, 2011, 1, 11.	1.3	34
44	Linking Radiation Oncology and Imaging through Molecular Biology (or Now That Therapy and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 46	3.6	33
45	Scarce Resources for Nuclear Detonation: Project Overview and Challenges. Disaster Medicine and Public Health Preparedness, 2011, 5, S13-S19.	0.7	33
46	Public Health and Medical Preparedness for a Nuclear Detonation. Health Physics, 2015, 108, 149-160.	0.3	33
47	Education and Training for Radiation Scientists: Radiation Research Program and American Society of Therapeutic Radiology and Oncology Workshop, Bethesda, Maryland, May 12â€“14, 2003. Radiation Research, 2003, 160, 729-737.	0.7	31
48	Medical Response to a Nuclear Detonation: Creating a Playbook for State and Local Planners and Responders. Disaster Medicine and Public Health Preparedness, 2011, 5, S89-S97.	0.7	31
49	Health Care System Planning for and Response to a Nuclear Detonation. Disaster Medicine and Public Health Preparedness, 2011, 5, S73-S88.	0.7	31
50	Radiation-induced Adaptive Response: New Potential for Cancer Treatment. Clinical Cancer Research, 2020, 26, 5781-5790.	3.2	30
51	Medical Planning and Response for a Nuclear Detonation: A Practical Guide. Biosecurity and Bioterrorism, 2012, 10, 346-371.	1.2	29
52	Radiation Survivors: Understanding and Exploiting the Phenotype following Fractionated Radiation Therapy. Molecular Cancer Research, 2013, 11, 5-12.	1.5	29
53	The International Cancer Expert Corps: A Unique Approach for Sustainable Cancer Care in Low and Lower-Middle Income Countries. Frontiers in Oncology, 2014, 4, 333.	1.3	29
54	Microarray analysis of miRNA expression profiles following whole body irradiation in a mouse model. Biomarkers, 2018, 23, 689-703.	0.9	28

#	Article	IF	Citations
55	Lessons Learned from Radiation Oncology Clinical Trials. Clinical Cancer Research, 2013, 19, 6089-6100.	3.2	27
56	Exploiting Radiation-Induced Signaling to Increase the Susceptibility of Resistant Cancer Cells to Targeted Drugs: AKT and mTOR Inhibitors as an Example. Molecular Cancer Therapeutics, 2018, 17, 355-367.	1.9	27
57	Can Radiation Risks to Patients Be Reduced Without Reducing Radiation Exposure? The Status of Chemical Radioprotectants. American Journal of Roentgenology, 2011, 196, 616-618.	1.0	25
58	Gene Expression Profile of Coronary Artery Cells Treated With Nonsteroidal Anti-inflammatory Drugs Reveals Off-target Effects. Journal of Cardiovascular Pharmacology, 2012, 59, 487-499.	0.8	25
59	Apoptosis and Clonogenic Cell Death in PC3 Human Prostate Cancer Cells after Treatment with Gamma Radiation and Suramin. Radiation Research, 1997, 148, 105.	0.7	24
60	Calculated prostate carcinoma volume. , 1998, 82, 334-341.		24
61	Using the Model of Resource and Time-Based Triage (MORTT) to Guide Scarce Resource Allocation in the Aftermath of a Nuclear Detonation. Disaster Medicine and Public Health Preparedness, 2011, 5, S98-S110.	0.7	24
62	Enhancing the Efficacy of Radiation Therapy: Premises, Promises, and Practicality. Journal of Clinical Oncology, 2014, 32, 2832-2835.	0.8	24
63	Signal transduction inhibitors as modifiers of radiation therapy in human prostate carcinoma xenografts. Radiation Oncology Investigations, 1996, 4, 221-230.	1.3	23
64	Adverse event reporting and developments in radiation biology after normal tissue injury: International Atomic Energy Agency consultation. International Journal of Radiation Oncology Biology Physics, 2006, 64, 1442-1451.	0.4	23
65	Long-term Tumor Adaptation after Radiotherapy: Therapeutic Implications for Targeting Integrins in Prostate Cancer. Molecular Cancer Research, 2018, 16, 1855-1864.	1.5	23
66	mRNA Expression Profiles for Prostate Cancer following Fractionated Irradiation Are Influenced by p53 Status. Translational Oncology, 2013, 6, 573-585.	1.7	22
67	Radiation Oncology–Linking Technology and Biology in the Treatment of Cancer. Acta OncolÃ³gica, 2002, 41, 6-13.	0.8	21
68	Chemical, Biological, Radiological, Nuclear, and Explosive (CBRNE) Science and the CBRNE Science Medical Operations Science Support Expert (CMOSSE). Disaster Medicine and Public Health Preparedness, 2019, 13, 995-1010.	0.7	21
69	Enhancing Career Paths for Tomorrow's Radiation Oncologists. International Journal of Radiation Oncology Biology Physics, 2019, 105, 52-63.	0.4	20
70	Analysis of lncRNA-miRNA-mRNA expression pattern in heart tissue after total body radiation in a mouse model. Journal of Translational Medicine, 2021, 19, 336.	1.8	20
71	National Cancer Institute (NCI) state of the science: Targeted radiosensitizers in colorectal cancer. Cancer, 2019, 125, 2732-2746.	2.0	19
72	Global Health in Radiation Oncology: The Emergence of a New Career Pathway. Seminars in Radiation Oncology, 2017, 27, 118-123.	1.0	18

#	Article	IF	Citations
73	Isoprostane levels in the urine of patients with prostate cancer receiving radiotherapy are not elevated. International Journal of Radiation Oncology Biology Physics, 2004, 58, 1536-1539.	0.4	17
74	Imaging and Data Acquisition in Clinical Trials for Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2016, 94, 404-411.	0.4	17
75	Radiation Injury Treatment Network (RITN): Healthcare professionals preparing for a mass casualty radiological or nuclear incident. International Journal of Radiation Biology, 2011, 87, 748-753.	1.0	16
76	United States medical preparedness for nuclear and radiological emergencies. Journal of Radiological Protection, 2021, 41, 1420-1434.	0.6	16
77	Transforming Science, Service, and Society. Science Translational Medicine, 2014, 6, 259fs42.	5.8	15
78	Bringing Cancer Care to the Underserved Globally: A Challenging Problem for Which Radiation Oncology Can Pioneer Novel Solutions. International Journal of Radiation Oncology Biology Physics, 2014, 89, 443-445.	0.4	15
79	Comprehensive molecular tumor profiling in radiation oncology: How it could be used for precision medicine. Cancer Letters, 2016, 382, 118-126.	3.2	15
80	53BP1/RIF1 signaling promotes cell survival after multifractionated radiotherapy. Nucleic Acids Research, 2020, 48, 1314-1326.	6.5	15
81	FLASH Radiation Therapy: New Technology Plus Biology Required. International Journal of Radiation Oncology Biology Physics, 2021, 110, 1248-1249.	0.4	15
82	Molecular Biology in Radiation Oncology: Radiation Oncology Perspective of BRCA1 and BRCA2. Acta OncolÃ³gica, 1999, 38, 55-59.	0.8	14
83	Fukushima and the Future of Radiation Research. Radiation Research, 2013, 179, 1-8.	0.7	14
84	Training Global Oncologists: Addressing the Global Cancer Control Problem. Frontiers in Oncology, 2015, 5, 80.	1.3	14
85	Proposed â€œExposure And Symptom Triageâ€•(EAST) Tool to Assess Radiation Exposure After a Nuclear Detonation. Disaster Medicine and Public Health Preparedness, 2018, 12, 386-395.	0.7	14
86	The lncRNAs LINC00261 and LINC00665 are upregulated in long-term prostate cancer adaptation after radiotherapy. Molecular Therapy - Nucleic Acids, 2021, 24, 175-187.	2.3	14
87	Modulating the Radiation Response. Stem Cells, 1996, 14, 10-15.	1.4	13
88	National Cancer InstituteÃ¢â‚¬â„¢s Cancer Disparities Research Partnership Program: Experience and Lessons Learned. Frontiers in Oncology, 2014, 4, 303.	1.3	13
89	Accurate, Precision Radiation Medicine: A Meta-Strategy for Impacting Cancer Care, Global Health, and Nuclear Policy and Mitigating Radiation Injury From Necessary Medical Use, Space Exploration, and Potential Terrorism. International Journal of Radiation Oncology Biology Physics, 2018, 101, 250-253.	0.4	13
90	Current and Future Initiatives for Radiation Oncology at the National Cancer Institute in the Era of Precision Medicine. International Journal of Radiation Oncology Biology Physics, 2018, 102, 18-25.	0.4	12

#	Article	IF	Citations
91	Decreasing the Toxicity of Radiation Therapy: Radioprotectors and Radiomitigators Being Developed by the National Cancer Institute Through Small Business Innovation Research Contracts. International Journal of Radiation Oncology Biology Physics, 2019, 104, 188-196.	0.4	12
92	Gene Expression Profiles from Heart, Lung and Liver Samples of Total-Body-Irradiated Minipigs: Implications for Predicting Radiation-Induced Tissue Toxicity. Radiation Research, 2020, 194, 411-430.	0.7	12
93	Phase III study of ibuprofen versus placebo for radiation-induced genitourinary side effects. International Journal of Radiation Oncology Biology Physics, 2002, 54, 191-194.	0.4	11
94	User-Managed Inventory: An Approach to Forward-Deployment of Urgently Needed Medical Countermeasures for Mass-Casualty and Terrorism Incidents. Disaster Medicine and Public Health Preparedness, 2012, 6, 408-414.	0.7	11
95	Recovery and Resilience After a Nuclear Power Plant Disaster: A Medical Decision Model for Managing an Effective, Timely, and Balanced Response. Disaster Medicine and Public Health Preparedness, 2013, 7, 136-145.	0.7	11
96	Prostate cancer. Technology versus biology. Cancer, 1993, 72, 305-309.	2.0	10
97	Assessing Surge Capacity for Radiation Victims with Marrow Toxicity. Biology of Blood and Marrow Transplantation, 2010, 16, 1436-1441.	2.0	9
98	Disaster Preparation: Lessons from Japan. Science, 2011, 332, 1379-1379.	6.0	9
99	Emergency medical preparedness for radiological/nuclear incidents in the United States. Journal of Radiological Protection, 2012, 32, N27-N32.	0.6	8
100	Response of the U.S. Department of Health and Human Services in Protecting Civilian Americans in Japan during the Fukushima Nuclear Crisis. Health Physics, 2012, 102, 570-579.	0.3	8
101	Radiationâ€"Therapeutic Agent Clinical Trials: Leveraging Advantages of a National Cancer Institute Programmatic Collaboration. Seminars in Radiation Oncology, 2016, 26, 271-280.	1.0	8
102	Overcoming Challenges in Providing Radiation Therapy to Patients With Cancer in Nigeria and Experience in the National Hospital Abuja, Nigeria. JCO Global Oncology, 2020, 6, 1232-1236.	0.8	8
103	Current Insights in Radiation Combination Therapies: Influence of Omics and Novel Targeted Agents in Defining New Concepts in Radiation Biology and Clinical Radiation Oncology. Seminars in Radiation Oncology, 2016, 26, 251-253.	1.0	7
104	Treatment, Not Terror: Time for Unique Problem-Solving Partnerships for Cancer Care in Resource-Challenged Environments. Journal of Global Oncology, 2017, 3, 687-691.	0.5	7
105	Long-term expression changes of immune-related genes in prostate cancer after radiotherapy. Cancer Immunology, Immunotherapy, 2022, 71, 839-850.	2.0	7
106	The Medical Student Perspective on Global Health Care in Radiation Oncology: Opportunities, Barriers to Sustainability, and Future Directions. International Journal of Radiation Oncology Biology Physics, 2014, 89, 492-494.	0.4	6
107	Moving Forward in the Next Decade: Radiation Oncology Sciences for Patient-Centered Cancer Care. JNCI Cancer Spectrum, 2021, 5, pkab046.	1.4	6
108	A Blueprint for Linking Academic Oncology and the Community. Journal of Health Politics, Policy and Law, 1998, 23, 973-994.	0.9	6

#	Article	IF	Citations
109	Preparedness for a â€˜no-noticeâ€™ mass-casualty incident: a nuclear detonation scenario. International Journal of Radiation Biology, 2022, 98, 873-877.	1.0	6
110	The verdict is in: the time for effective solutions to the global cancer burden is now. Lancet Oncology, The, 2015, 16, 1146-1147.	5.1	5
111	Exploiting Gene Expression Kinetics in Conventional Radiotherapy, Hyperfractionation, and Hypofractionation for Targeted Therapy. Seminars in Radiation Oncology, 2016, 26, 254-260.	1.0	5
112	A Broad Impact for Global Oncology. JAMA Oncology, 2019, 5, 1397.	3.4	5
113	Radiation Biomarkers: Can Small Businesses Drive Accurate Radiation Precision Medicine?. Radiation Research, 2020, 193, 199.	0.7	5
114	Whole blood gene expression within days after total-body irradiation predicts long term survival in Gottingen minipigs. Scientific Reports, 2021, 11, 15873.	1.6	5
115	Radiation Oncology in the 21st Century: Prospective Randomized Trials That Changed Practiceâ€¦ or Didnâ€™t!. Frontiers in Oncology, 2018, 8, 130.	1.3	4
116	Achieving flexible competence: bridging the investment dichotomy between infectious diseases and cancer. BMJ Global Health, 2020, 5, e003252.	2.0	4
117	Modulating the Radiation Response. Oncologist, 1996, 1, 227-231.	1.9	4
118	Radiotherapy alters expression of molecular targets in prostate cancer in a fractionation- and time-dependent manner. Scientific Reports, 2022, 12, 3500.	1.6	4
119	Registering Molecular Imaging Information into Anatomic Images with Improved Spatial Accuracy. , 2007, , .		3
120	Mentors, Mensches, and Models. International Journal of Radiation Oncology Biology Physics, 2009, 73, 974-975.	0.4	3
121	The Road Not Taken and Choices in Radiation Oncology. Oncologist, 2010, 15, 332-337.	1.9	3
122	Foreword. Disaster Medicine and Public Health Preparedness, 2011, 5, S11-S12.	0.7	3
123	Masters of Our Destiny: From Jazz Quartet to Symphony Orchestra. International Journal of Radiation Oncology Biology Physics, 2016, 96, 511-513.	0.4	3
124	National Cancer Institute support for targeted alpha-emitter therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 49, 64-72.	3.3	3
125	The Radiation Stress Response: Of the People, By the People and For the People. Radiation Research, 2017, 187, 129-146.	0.7	2
126	Guidance, Training and Exercises for Responding to an Improvised Nuclear Device. Health Physics, 2018, 114, 165-172.	0.3	2

#	Article	IF	Citations
127	Global health and cancer. Lancet, The, 2019, 393, 983-984.	6.3	2
128	Eli J. Glatstein: A Steward Extraordinaire of Radiation Oncology. International Journal of Radiation Oncology Biology Physics, 2020, 107, 1-5.	0.4	2
129	Capturing Acquired Wisdom, Enabling Healthful Aging, and Building Multinational Partnerships Through Senior Global Health Mentorship. Global Health, Science and Practice, 2020, 8, 626-637.	0.6	2
130	Low-dose radiotherapy for COVID-19 pneumonia and cancer: summary of a recent symposium and future perspectives. International Journal of Radiation Biology, 2023, 99, 357-371.	1.0	2
131	Commentary on the Combined Disaster in Japan1. Radiation Research, 2012, 177, 15-17.	0.7	1
132	Sixteenth Annual Warren K. Sinclair Keynote Address: Frontiers in Medical Radiation Science. Health Physics, 2020, 118, 349-353.	0.3	1
133	Research-Driven Radiation Oncology: A Narrative on the Ongoing Legacy of Henry S. Kaplan. International Journal of Radiation Oncology Biology Physics, 2021, 109, 10-14.	0.4	1
134	Overview and Lessons From the Preclinical Chemoradiotherapy Testing Consortium. International Journal of Radiation Oncology Biology Physics, 2021, 111, 1126-1130.	0.4	1
135	In Reply to Breneman et al. International Journal of Radiation Oncology Biology Physics, 2021, 110, 1545-1546.	0.4	1
136	Radiological and Nuclear Terrorism: Relevance to the Radiation Oncology and Biology Communities. Medical Radiology, 2014, , 293-311.	0.0	1
137	Tumor Heterogeneity Research and Innovation in Biologically Based Radiation Therapy From the National Cancer Institute Radiation Research Program Portfolio. Journal of Clinical Oncology, 2022, 40, 1861-1869.	0.8	1
138	Implementing Cancer Care for the Undeserved Globally: From the â€œ5 Râ€™sâ€•of Radiobiology to the â€œ7 Pâ€™sâ€• of Global Cancer Care. Seminars in Radiation Oncology, 2017, 27, 95-97.	1.0	0
139	The Call. Practical Radiation Oncology, 2018, 8, 1-3.	1.1	0
140	Career Options in Radiation Oncology. , 2021, , 3-16.		0
141	SU-FF-J-74: High Accuracy of Volumetric Image Registration of CT, MR and PET Images. Medical Physics, 2006, 33, 2037-2037.	1.6	0
142	Eli J. Glatstein: Inspiring and Provoking Critical Thinking. Radiation Research, 2020, 193, 318.	0.7	0
143	Medical Countermeasures to Radiation Injury. , 2008, , 11-17.		0
144	Tribulations and Trials: The Implementation of Biologically Dependent Radiation Therapy Technologies. International Journal of Radiation Oncology Biology Physics, 2022, , .	0.4	0